Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia

Citation
Mp. Rosin et al., Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia, CLIN CANC R, 6(2), 2000, pp. 357-362
Citations number
19
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
CLINICAL CANCER RESEARCH
ISSN journal
1078-0432 → ACNP
Volume
6
Issue
2
Year of publication
2000
Pages
357 - 362
Database
ISI
SICI code
1078-0432(200002)6:2<357:UOALTP>2.0.ZU;2-R
Abstract
One of the best approaches to identifying genetic changes critical to oral cancer progression is to compare progressing and nonprogressing oral premal ignant lesions, However, such samples are rare, and they require long-term follow-up. The current study used the large archive network and clinical da tabase in British Columbia to study loss of heterozygosity (LOH) in cases o f early oral premalignancies, comparing those with a history of progression to carcinoma irt situ or invasive cancer and those without a history of pr ogression (referred to as nonprogressing cases). Each of 116 cases was anal yzed for LOH at 19 microsatellite loci on seven chromosome arms (3p, 4q, gp , 9p, 11q, 13q, and 17p), The progressing and nonprogressing cases showed d ramatically different LOH patterns of multiple allelic losses, An essential step for progression seems to involve LOH at 3p and/or 9p because virtuall y all progressing cases showed such loss. However, LOH at 3p and/or 9p also occurred in nonprogressing cases. Individuals with LOH at 3p and/or 9p but at no other arms exhibit only a slight increase of 3.8-fold in relative ri sk for developing cancer. In contrast, individuals with additional losses ( on 4q, 8p, 11q, or 17p), which appeared uncommon in nonprogressing cases, s howed 33-fold increases in relative cancer risk. In conclusion, analysis of LOH at 3p and 9p could serve as an initial screening for cancer risk of ea rly premalignancies. Follow-up investigation for additional losses would be essential for predicting cancer progression.